background
background
RLMD
Relmada Therapeutics Inc
$0.3670
-0.0030
-0.81%
Earnings Expectation?
Beat
Meet
Miss
Expected Price Action?
Up
Flat
Down
Wednesday
December 4, 2024
7:30 AM ET
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
Thursday
November 7, 2024
4:10 PM ET
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Monday
November 4, 2024
4:30 PM ET
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Wednesday
August 7, 2024
4:05 PM ET
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Wednesday
August 7, 2024
4:05 PM ET
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Monday
August 5, 2024
7:30 AM ET
Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024